Prolifération vitréo-rétinienne : traitement préventif

Chiquet, Christophe; Rouberol, F.

doi:10.1016/j.jfo.2014.04.003

Cited by 4 publications

(4 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of gradual improvements in surgical success rates over the past decades, PVR remains a major barrier to successful repair of retinal detachments (RD), with an incidence of 5–11% [2]. Moreover, it is implicated in over 75% of postsurgical redetachments [2, 3]. Multiple strategies, including surgery, have been developed to inhibit this disease process.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations

2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…PVR surgery can be challenging, even for experienced vitreoretinal surgeons, and anatomic success does not necessarily lead to functional improvement [2]. Adjunctive pharmacotherapy, with new molecules and delivery systems, offers promise for improved outcomes [3]. Animal models have an essential role in screening of various drugs [4].…”

Section: Introductionmentioning

confidence: 99%

Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations

2018

View full text Add to dashboard Cite

show abstract

“…The success of retinal detachment (RD) surgery is dependent on the absence or control of proliferative vitreoretinopathy (PVR) [1]. PVR, one of the most important complications following vitreoretinal surgery, is a fibrotic eye disease with an incidence of 5-11%, and characterized by migration and proliferation of cells following a break in the retina or trauma, leading to formation of membranes in the periretinal area, followed by contraction of the cellular membranes and traction on the retina that causes RD [2][3][4]. For improvements in the surgical success rate and prevention of this complication, it is necessary to understand the risk factors for PVR in patients after RD surgery.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: A systematic review and meta-analysis

Xiang,

Fan,

Wang

2023

PLoS ONE

View full text Add to dashboard Cite

Background To comprehensively investigate risk factors for proliferative vitreoretinopathy (PVR) after retinal detachment (RD) surgery. Methods PubMed, Embase, Cochrane Library, and Web of Science were systematically searched until May 22, 2023. Risk factors included demographic and disease-related risk factors. Odds ratios (ORs) and weighted mean differences (WMDs) were used as the effect sizes, and shown with 95% confidence intervals (CIs). Sensitivity analysis was conducted. The protocol was registered with PROSPERO (CRD42022378652). Results Twenty-two studies of 13,875 subjects were included in this systematic review and meta-analysis. Increased age was associated with a higher risk of postoperative PVR (pooled WMD = 3.98, 95%CI: 0.21, 7.75, P = 0.038). Smokers had a higher risk of postoperative PVR than non-smokers (pooled OR = 5.07, 95%CI: 2.21–11.61, P<0.001). Presence of preoperative PVR was associated with a greater risk of postoperative PVR (pooled OR = 22.28, 95%CI: 2.54, 195.31, P = 0.005). Presence of vitreous hemorrhage was associated with a greater risk of postoperative PVR (pooled OR = 4.12, 95%CI: 1.62, 10.50, P = 0.003). Individuals with aphakia or pseudophakia had an increased risk of postoperative PVR in contrast to those without (pooled OR = 1.41, 95%CI: 1.02, 1.95, P = 0.040). The risk of postoperative PVR was higher among patients with macula off versus those with macula on (pooled OR = 1.85, 95%CI: 1.24, 2.74, P = 0.002). Extent of RD in patients with postoperative PVR was larger than that in patients without (pooled WMD = 0.31, 95%CI: 0.02, 0.59, P = 0.036). Patients with postoperative PVR had longer duration of RD symptoms than those without (pooled WMD = 10.36, 95%CI: 2.29, 18.43, P = 0.012). Conclusion Age, smoking, preoperative PVR, vitreous hemorrhage, aphakia or pseudophakia, macula off, extent of RD, and duration of RD symptoms were risk factors for postoperative PVR in patients undergoing RD surgery, which may help better identify high-risk patients, and provide timely interventions.

show abstract

“…Five percent to 11% of patients with retinal detachment develop PVR. 1 Contraction of the proliferative membranes in PVR can lead to retinal detachment, which often results in significant vision loss. 2 Surgery is currently the most effective treatment for PVR but PVR often relapses.…”

mentioning

confidence: 99%

Silibinin Prevents TGFβ-Induced EMT of RPE in Proliferative Vitreoretinopathy by Inhibiting Stat3 and Smad3 Phosphorylation

Ma,

Xie,

Gong

et al. 2023

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Purpose The purpose of this study was to investigate the effects of silibinin on epithelial-mesenchymal transition (EMT) of retinal pigment epithelial (RPE) and proliferative vitreoretinopathy (PVR) formation, as well as its underlying molecular mechanism. Methods Cellular morphological change and EMT molecular markers were evaluated by using phase contrast imaging, qPCR, and Western blot (WB) to investigate the impact of silibinin on the EMT of ARPE-19 cells. Scratch assay and transwell assay were used to study the effect of silibinin on cell migration. An intravitreally injected RPE-induced rat PVR model was used to assess the effect of silibinin on PVR in vivo. RNA-seq was applied to study the molecular mechanism of silibinin-mediated PVR prevention. Results Silibinin inhibited TGFβ1-induced EMT and migration of RPE in a dose-dependent manner in vitro. Moreover, silibinin prevented proliferative membrane formation in an intravitreal injected RPE-induced rat PVR model. In line with these findings, RNA-seq revealed a global suppression of TGFβ1-induced EMT and migration-related genes by silibinin in RPEs. Mechanistically, silibinin reduced TGFβ1-induced phosphorylation levels of Smad3 and Stat3, and Smad3 nuclear translocation in RPE. Conclusions Silibinin inhibits the EMT of RPE cells in vitro and prevents the formation of PVR membranes in vivo. Mechanistically, silibinin inhibits Smad3 phosphorylation and suppresses Smad3 nuclear translocation through the inhibition of Stat3 phosphorylation. These findings suggest that silibinin may serve as a potential treatment for PVR.

show abstract

Prolifération vitréo-rétinienne : traitement préventif

Cited by 4 publications

References 73 publications

Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations

Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations

Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: A systematic review and meta-analysis

Silibinin Prevents TGFβ-Induced EMT of RPE in Proliferative Vitreoretinopathy by Inhibiting Stat3 and Smad3 Phosphorylation

Contact Info

Product

Resources

About